The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Validation of the NCI patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE) in women receiving treatment for metastatic breast cancer.
Sandra A. Mitchell
No relevant relationships to disclose
Kathy Lang
Research Funding - Genentech
Christine Nichols
Research Funding - Genentech
Steven B. Clauser
No relevant relationships to disclose
Victoria Federico
Research Funding - Genentech
Deepa Lalla
Employment or Leadership Position - Genentech
Stock Ownership - Roche
Debu Tripathy
No relevant relationships to disclose
Sara A. Hurvitz
Research Funding - GlaxoSmithKline; Roche
Other Remuneration - Roche
Kathleen M. Castro
No relevant relationships to disclose
Bryce B. Reeve
No relevant relationships to disclose
Lauren J. Rogak
No relevant relationships to disclose
Andrea Denicoff
No relevant relationships to disclose
Alice Chen
No relevant relationships to disclose
Richard Piekarz
No relevant relationships to disclose
Antonia V Bennett
No relevant relationships to disclose
Thomas Michael Atkinson
No relevant relationships to disclose
Ann M. O'Mara
No relevant relationships to disclose
Lori M. Minasian
No relevant relationships to disclose
Ethan M. Basch
No relevant relationships to disclose